Literature DB >> 18536718

Structure of and influence of a tick complement inhibitor on human complement component 5.

Folmer Fredslund1, Nick S Laursen, Pietro Roversi, Lasse Jenner, Cristiano L P Oliveira, Jan S Pedersen, Miles A Nunn, Susan M Lea, Richard Discipio, Lars Sottrup-Jensen, Gregers R Andersen.   

Abstract

To provide insight into the structural and functional properties of human complement component 5 (C5), we determined its crystal structure at a resolution of 3.1 A. The core of C5 adopted a structure resembling that of C3, with the domain arrangement at the position corresponding to the C3 thioester being very well conserved. However, in contrast to C3, the convertase cleavage site in C5 was ordered and the C345C domain flexibly attached to the core of C5. Binding of the tick C5 inhibitor OmCI to C5 resulted in stabilization of the global conformation of C5 but did not block the convertase cleavage site. The structure of C5 may render possible a structure-based approach for the design of new selective complement inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536718     DOI: 10.1038/ni.1625

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  55 in total

1.  Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex.

Authors:  Alexander E Aleshin; Richard G DiScipio; Boguslaw Stec; Robert C Liddington
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

2.  Inhibiting alternative pathway complement activation by targeting the factor D exosite.

Authors:  Kenneth J Katschke; Ping Wu; Rajkumar Ganesan; Robert F Kelley; Mary A Mathieu; Philip E Hass; Jeremy Murray; Daniel Kirchhofer; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

3.  Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.

Authors:  Nick S Laursen; Kasper R Andersen; Ingke Braren; Edzard Spillner; Lars Sottrup-Jensen; Gregers R Andersen
Journal:  EMBO J       Date:  2011-01-07       Impact factor: 11.598

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  Mimer: an automated spreadsheet-based crystallization screening system.

Authors:  Ditlev Egeskov Brodersen; Gregers Rom Andersen; Christian Brix Folsted Andersen
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-06-29

6.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

7.  Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.

Authors:  Nick S Laursen; Natasha Gordon; Stefan Hermans; Natalie Lorenz; Nicola Jackson; Bruce Wines; Edzard Spillner; Jesper B Christensen; Morten Jensen; Folmer Fredslund; Mette Bjerre; Lars Sottrup-Jensen; John D Fraser; Gregers R Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

Review 8.  C4a: An Anaphylatoxin in Name Only.

Authors:  Scott R Barnum
Journal:  J Innate Immun       Date:  2015-02-06       Impact factor: 7.349

9.  Structural basis for activation of the complement system by component C4 cleavage.

Authors:  Rune T Kidmose; Nick S Laursen; József Dobó; Troels R Kjaer; Sofia Sirotkina; Laure Yatime; Lars Sottrup-Jensen; Steffen Thiel; Péter Gál; Gregers R Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

10.  Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.

Authors:  Suzan H M Rooijakkers; Jin Wu; Maartje Ruyken; Robert van Domselaar; Karel L Planken; Apostolia Tzekou; Daniel Ricklin; John D Lambris; Bert J C Janssen; Jos A G van Strijp; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.